

# **Innovation Framework**

# Ideation

Ideas we believe in

# The general situation

The circumstances the world is in

- Obesity is a growing driver of colossal health & economic burden globally
- Current management is ineffective & too expensive
- Discovery of GLP-1RAs has opened new opportunities
- · Current market is dominated by a duopoly
- Disruptive innovation is an attractive opportunity

#### **Purpose**

Reduce the physical, emotional & economic burdens of obesity -thereby creating value for all stakeholders

#### Capabilities that matter

- Disruptive innovation
- Efficient, multidisciplinary evidence generation
- Low-cost high-scale manufacturing
- Delivering great consumer experiences

#### Vision

Consumers – particularly those with health risk from obesity - have a great experience losing weight, sustaining it and improving their lives at affordable cost long term

#### Quality

We care & our stakeholders & partners experience that caring

#### Goals by 2050

- Reverse or prevent 5M cases of T2DM
- Reduce 25 million life years lost per year
- Reduce direct health costs by \$100B
- While generating \$50B shareholder value

#### Identity

• We are empathetic, data-driven, disruptive & trustworthy

# **Core Business Process**

How we intend to create value

### **Identify** needs

#### What is the job to be done?

- Reduce obesity-inducing intake
- Change life-long behaviors

### What are the specific innovation opportunities?

- Reduced disutility
- Scaling

#### What is the customer (including consumer) value proposition?

• Better life (tbd)

# **Develop solutions**

# Target profile of solution

- Easier to use
- More tolerable
- Just as or more effective
- Lower cost

#### Search for & secure technology

- Oral delivery
- Lowest possible COGs

#### • GLP-1RA & combinations

#### Generate evidence with customers & consumers & other stakeholders

- Efficient data generation
- Stakeholder participation

# Manage change

consumers & other stakeholders

Measure impact with customers

Iterate core business process

# **Strategy**

What we choose to focus on

	Specific situation	Main choices	Action plans
Competitive	Massive global market     Growing Wegovy / Mounjaro     Scale & cost of goods matter     Duopoly (others entering)     Activated consumers     Defensive payers	Global strategy day-1 Benchmark everything Low PPE investment Disruptive innovation Engage consumers Partner with payers	Develop multiple products     Super-efficient evidence generation.     Manufacture via partners     Attack disutility     Execute consumer launch     Engage payers up-front
Human	Biopharma + consumerism     Lifelong consumer quest	Multidisciplinary talent     Provide lifelong engagement	Recruit & empower diversity     Create compelling     experience
Financial	Capital intensive     Risk of dilution	Build leading syndicates     Tranche with value step-ups     Access public markets early	Active constant engagement     Just-in-time financing     Run it like its already public
Communications	Major current coverage     Likely over-exuberance	Stay quiet until POC     Simple measured messages	Prepare for fund-raising, consumers, and payers